BIO TECH PUBLIC

Bio tech going public

Bio tech going public

Rigel is a clinical-stage drug development company which deals with discovering and developing novel, small-molecule drugs for the treatment of autoimmune diseases, muscle disorders and inflammatory diseases.

Details of the business

The URL of the website is http://www.rigel. This company comprises of 140 motivated employees who are present for the service of the company benefit.

Products

This company deals with pharmaceutical which are used for the treatment of diseases. These include the following:

Fostamatinib/ R788 (Rheumatoid Arthritis), R3434 (Asthma), JAK3 Inhibitor(transplant), JAK 3 Inhibitor (Discoid Lupus), PKC Inhibitor (Multiple Sclerosis), ACVR2ß Inhibitor (Muscle Atrophy), AMPK Activator (Muscle indurance) (www.rigel.com, 2011).

Publicity & Public Info

Rigel has always been into news as it takes part in conference and various events for recognition. Recently Rigel has participated in two upcoming news investor events. Rigel has always been an active participant in health conference. It is also focusing in developing new therapies for various diseases and it is also a stock company which deals with the stocks. This company is active as it also posts its financial statement on yearly basis and they are continuously renewed.

Collaborators

Rigel has signed partnerships with several leading pharmaceutical companies including, AstraZeneca, Pfizer, Merck, Johnson & Johnson, Novartis and Daiichi Sankyo. During its collaborations with many of these organizations, they added new programs or extended their relationship with Rigel beyond the scope of the initial agreements. To date Rigel has received over $260 million from collaborations. These partnerships are in addition to Rigel's own proprietary research and product development programs (www.rigel.com, 2011).

Competitors

The major competitors of the company are:

Janssen Biotech, Inc.Amgen Inc.Celgene Signal Researchare the major pharmaceuticals companies which are competitors of the company. These companies are a big threat to Rigel as they have a strong market position. These companies continuously focus on market expansion.

Financial Timeline

Rigel Pharmaceutical ...